Amgen Inc. has reported new 5,6- and 6,6-fused bicyclic alcohols and ethers acting as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors. They are reported to be useful for the treatment of gastrointestinal disorders.
Researchers from Universita degli Studi di Pavia and Universita degli Studi di Torino have prepared and tested new boron-based compounds for the treatment of Alzheimer’s disease by capture-enhanced neutron irradiation (CENI).
Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others.
Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.
TRAF2- and NCK-interacting kinase (TNIK) has been reported as a therapeutic target for colorectal cancer and, more recently, for lung squamous cell carcinoma, triple-negative breast cancer, or ovarian cancer, among others, especially in combination with inhibiting cancer-related kinases.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Congruence Therapeutics Inc. to generate novel small-molecule correctors against multiple protein targets in the oncology area.
The reversible transition between glioblastoma tumor-initiating cells, also known as glioma stem cells (GSCs), and differentiated glioma cells due to epigenetic modifications is one of the challenges in the development of effective glioma treatments.
RSS
